サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1499414

膠原病血管疾患市場：製品、適応症、最終用途別-2024-2030年の世界予測

Collagen Vascular Diseases Market by Product (Diagnosis, Treatments), Indication (Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa), End-Use - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 184 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=155.13円
膠原病血管疾患市場：製品、適応症、最終用途別-2024-2030年の世界予測
出版日: 2024年06月05日
発行: 360iResearch
ページ情報: 英文 184 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

膠原病血管疾患市場規模は2023年に298億3,000万米ドルと推計され、2024年には322億1,000万米ドルに達し、CAGR 8.70％で2030年には535億1,000万米ドルに達すると予測されます。

膠原病血管疾患は、臓器や身体の他の部分を支えるタンパク質を多く含む組織が関与する疾患群です。この結合組織は、皮膚、腱、骨、軟骨、血管の強度、弾力性、構造に不可欠です。膠原病血管疾患は、遺伝性のものや、免疫システムの過剰な働きによって引き起こされるものがあり、その結果、身体が自分自身の組織を攻撃してしまう自己免疫疾患になることがあります。これらの疾患には、罹患した臓器や組織を損傷し機能不全に陥らせる炎症を含む共通の特徴があることが多いです。このカテゴリーには、関節リウマチ、強皮症、全身性エリテマトーデス、多発性筋炎、皮膚筋炎、全身性硬化症など、様々な疾患が含まれます。膠原病血管疾患市場は、結合組織に影響を及ぼす疾患を対象とした診断、治療、治療薬、サービスなどの医療ソリューションの需要と供給を包含します。この市場の用途には、臨床診断、治療、継続的な患者管理が含まれます。エンドユーザーは通常、病院、診療所、リウマチ専門センター、在宅ケア環境などのヘルスケア施設です。この市場はまた、研究機関や学術機関、新しい治療法の開発に携わる製薬企業やバイオテクノロジー企業にもサービスを提供しています。膠原病血管疾患市場のニーズに影響を与える主な要因としては、膠原病血管疾患に対する認識と理解の高まり、世界の自己免疫疾患の罹患率の上昇、ヘルスケアインフラの改善、医療サービスへのアクセシビリティの向上などが挙げられます。しかし、先進的な治療や投薬に伴う高額な費用、政府の厳しい規制や承認プロセスなどの課題に直面しています。一方、膠原病血管疾患のニーズは、遺伝子治療や幹細胞治療の進歩、患者管理のための遠隔医療、モバイルヘルスアプリケーション、ウェアラブルの採用など、いくつかの急成長する機会を提示しています。

主な市場の統計
基準年［2023] 298億3,000万米ドル
予測年［2024] 322億1,000万米ドル
予測年 [2030] 535億1,000万米ドル
CAGR（%） 8.70%

地域別の洞察

米国は、確立されたヘルスケア・インフラ、患者の意識、自己免疫疾患の罹患率の高さなどを背景に、CVDの重要な市場となっています。技術革新に注力する大手製薬企業の存在と政府の支援政策が市場拡大に寄与しています。南米では、ヘルスケアへのアクセスが改善し、国民の疾患に対する意識が高まるにつれて膠原病血管疾患市場が拡大しています。ヘルスケア提供の強化に向けた政府の取り組みや、医学研究のための国際的な協力関係が、市場をさらに押し上げると予想されます。EUのKEYWORDに対するニーズは、国民皆保険制度が利用可能であることと、研究開発に力を入れていることが特徴です。医薬品の承認に関する厳しい規制が、高水準の医療を保証しています。この地域の消費者は最先端の治療施設を期待し、治療の有効性と安全性プロファイルに後押しされています。中東では膠原病血管疾患を含む自己免疫疾患が増加しており、ヘルスケア部門が発展しているため、国際的なガイドラインや医薬品への依存度が高いです。アフリカでは膠原病血管疾患の管理能力にばらつきがあり、多くの地域でこれらの疾患の有病率が高く、先進治療が不足しています。中国市場は、近代的なヘルスケアシステムへの移行に伴い急速に拡大しており、政府および民間セクターによるヘルスケアへの投資の増加と、世界医薬品へのアクセスの向上が顧客ニーズに影響を及ぼしています。日本市場は、ヘルスケアにおける高度な技術統合を反映しており、消費者層はイノベーションと治療の質に傾斜しています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは、膠原病血管疾患市場におけるベンダーのポジショニングを評価する上で不可欠です。このマトリックスはベンダーの包括的な評価を提供し、事業戦略や製品満足度に関連する重要な指標を検証します。この詳細な評価により、ユーザーは自らの要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功のレベルを表す4つの象限、すなわちForefront（F）、Pathfinder（P）、Niche（N）、Vital（V）に分類されます。

市場シェア分析

市場シェア分析は、膠原病血管疾患市場におけるベンダーの現状について、洞察に満ちた詳細な評価を提供する包括的なツールです。ベンダーの貢献度を綿密に比較・分析することで、各ベンダーの業績や市場シェア争いの際に直面する課題について、より深い理解を得ることができます。これらの貢献には、全体的な収益、顧客ベース、その他の重要な指標が含まれます。さらに、この分析では、調査した基準年の期間に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合性に関する貴重な考察を提供しています。このような詳細な情報を得ることで、ベンダーは市場競争において優位に立つために、より多くの情報に基づいた意思決定を行い、効果的な戦略を考案することができます。

戦略分析と推奨

戦略分析は、世界マーケットで確固たる足場を築こうとする組織にとって不可欠です。企業は、膠原病血管疾患市場における現在の地位を徹底的に評価することで、長期的な願望に沿った情報に基づいた意思決定を行うことができます。この重要な評価には、組織のリソース、能力、全体的なパフォーマンスを徹底的に分析し、中核となる強みと改善すべき領域を特定することが含まれます。

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 膠原病血管疾患に対する認識と理解の高まり
      • 自己免疫疾患の発症率が世界的に上昇
      • ヘルスケアインフラの改善と医療サービスへのアクセスの向上
    • 抑制要因
      • 高度な治療や薬剤に関連する高額な費用
    • 機会
      • 遺伝子および幹細胞治療の継続的な進歩
      • 患者管理のための遠隔医療、モバイルヘルスアプリケーション、ウェアラブルの導入
    • 課題
      • 厳格な政府規制と承認プロセス
  • 市場セグメンテーション分析
    • 製品：膠原病血管疾患における生検キットの使用増加
    • 適応症：皮膚筋炎の適応症としての利用が増加中
    • 最終用途：さまざまな健康状態を診断するための診断センターや研究所での使用拡大
  • 市場ディスラプション分析
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 価格分析
  • 技術分析
  • 特許分析
  • 貿易分析
  • 規制枠組みの分析

第6章 膠原病血管疾患市場：製品別

  • 診断
  • 治療

第7章 膠原病血管疾患市場適応症別

  • 強直性脊椎炎
  • 皮膚筋炎
  • 結節性多発動脈炎
  • 多発性筋炎
  • 乾癬性関節炎
  • 再発性多発軟骨炎
  • 関節リウマチ
  • 強皮症
  • 全身性エリテマトーデス
  • 血管炎

第8章 膠原病血管疾患市場：最終用途別

  • 診断センターおよび検査室
  • 病院・クリニック

第9章 南北アメリカの膠原病血管疾患市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の膠原病血管疾患市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの膠原病血管疾患市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • 市場シェア分析2023
  • FPNVポジショニングマトリックス, 2023
  • 競合シナリオ分析
    • クエスト・ダイアグノスティクスとサイファー・メディシンが提携し、関節リウマチ患者への精密医療へのアクセスを拡大
    • FDA、関節リウマチ、若年性関節リウマチの治療薬として初のトシリズマブバイオシミラーを承認
    • アメリカリウマチ学会が関節リウマチの転帰を測定するための新しいツールキットを発表
  • 戦略分析と提言

第13章 競合ポートフォリオ

  • 主要企業プロファイル
  • 主要製品ポートフォリオ
図表

LIST OF FIGURES

  • FIGURE 1. COLLAGEN VASCULAR DISEASES MARKET RESEARCH PROCESS
  • FIGURE 2. COLLAGEN VASCULAR DISEASES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. COLLAGEN VASCULAR DISEASES MARKET DYNAMICS
  • FIGURE 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. COLLAGEN VASCULAR DISEASES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 22. COLLAGEN VASCULAR DISEASES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. COLLAGEN VASCULAR DISEASES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOPSY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BIOPSY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY BLOOD TEST, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ECHOCARDIOGRAM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY IMAGING TESTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY URINALYSIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY URINALYSIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PHYSICAL THERAPY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY ANKYLOSING SPONDYLITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DERMATOMYOSITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DERMATOMYOSITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYARTERITIS NODOSA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYARTERITIS NODOSA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYMYOSITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY POLYMYOSITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RELAPSING POLYCHONDRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RELAPSING POLYCHONDRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SCLERODERMA, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SCLERODERMA, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY SYSTEMIC LUPUS ERYTHEMATOSUS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY VASCULITIS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 71. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 72. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 81. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 82. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 83. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 84. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 91. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 92. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 93. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 94. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 95. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 96. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 101. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 102. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 103. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 104. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 105. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 106. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 107. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 108. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 111. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 112. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 113. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 114. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 115. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 116. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 117. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 118. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 119. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 120. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 135. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 136. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 137. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 138. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 139. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 140. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 141. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 142. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 143. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 144. AUSTRALIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 145. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 146. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 147. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 148. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 149. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 150. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 151. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 152. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 153. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 154. CHINA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 155. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 156. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 157. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 158. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 159. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 160. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 161. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 162. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 163. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 164. INDIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 165. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 166. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 167. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 168. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 169. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 170. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 171. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 172. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 173. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 174. INDONESIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 175. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 176. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 177. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 178. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 179. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 180. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 181. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 182. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 183. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 184. JAPAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 185. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 186. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 187. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 188. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 189. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 190. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 191. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 192. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 193. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 194. MALAYSIA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 195. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 196. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 197. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 198. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 199. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 200. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 201. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 202. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 203. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 204. PHILIPPINES COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 205. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 206. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 207. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 208. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 209. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 210. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 211. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 212. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 213. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 214. SINGAPORE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 215. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 216. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 217. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 218. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 219. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 220. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 221. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 222. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 223. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 224. SOUTH KOREA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 225. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 226. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 227. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 228. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 229. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 230. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 231. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 232. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 233. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 234. TAIWAN COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 235. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 236. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 237. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 238. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 239. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 240. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 241. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 242. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 243. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 244. THAILAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 245. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 246. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 247. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 248. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 249. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 250. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 251. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 252. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 253. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 254. VIETNAM COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 255. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 256. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 257. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 258. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 259. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 260. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 261. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 262. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 263. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 264. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 265. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 266. EUROPE, MIDDLE EAST & AFRICA COLLAGEN VASCULAR DISEASES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 267. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 268. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 269. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 270. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 271. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 272. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 273. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 274. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 275. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 276. DENMARK COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 277. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 278. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 279. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 280. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 281. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 282. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 283. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 284. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 285. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 286. EGYPT COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 287. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 288. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 289. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 290. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 291. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 292. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 293. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 294. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 295. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 296. FINLAND COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 297. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 298. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 299. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 300. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 301. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 302. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 303. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 304. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 305. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 306. FRANCE COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 307. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 308. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 309. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 310. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 311. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 312. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 313. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 314. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 315. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 316. GERMANY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 317. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 318. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 319. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 320. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2024-2030 (USD MILLION)
  • TABLE 321. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2018-2023 (USD MILLION)
  • TABLE 322. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY TREATMENTS, 2024-2030 (USD MILLION)
  • TABLE 323. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
  • TABLE 324. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
  • TABLE 325. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 326. ISRAEL COLLAGEN VASCULAR DISEASES MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 327. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 328. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 329. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2018-2023 (USD MILLION)
  • TABLE 330. ITALY COLLAGEN VASCULAR DISEASES MARKET SIZE, BY DIAGNOSIS, 2
目次
Product Code: MRR-144C638C8F82

[184 Pages Report] The Collagen Vascular Diseases Market size was estimated at USD 29.83 billion in 2023 and expected to reach USD 32.21 billion in 2024, at a CAGR 8.70% to reach USD 53.51 billion by 2030.

Collagen vascular diseases comprise a group of disorders that involve the protein-rich tissue that supports organs and other parts of the body. This connective tissue is essential for the strength, elasticity, and structure of skin, tendons, bones, cartilage, and blood vessels. Collagen vascular diseases can be hereditary or caused by an overactive immune system, resulting in autoimmune conditions where the body attacks its own tissues. These diseases often share common features, including inflammation, which can damage and dysfunction of affected organs and tissues. The category encompasses a variety of conditions, including rheumatoid arthritis, scleroderma, systemic lupus erythematosus, polymyositis, dermatomyositis, and systemic sclerosis, among others. The market for collagen vascular diseases encompasses the demand and supply of medical solutions, including diagnostics, treatments, therapeutics, and services targeted towards diseases that affect connective tissue. Applications for this market include clinical diagnostics, therapeutic treatments, and ongoing patient management. End-users are typically healthcare facilities like hospitals, clinics, specialized rheumatology centers, and home care settings. This market also serves research and academic institutions and pharmaceutical and biotechnology companies involved in the development of new treatments. The key factors influencing the need for the collagen vascular diseases market include growing awareness and understanding of collagen vascular diseases, rising incidence of autoimmune diseases globally, improved healthcare infrastructure, and increased accessibility to medical services. However, the market faces challenges, such as high costs associated with advanced treatments and medications and stringent government regulations and approval processes. On the other hand, the need for collagen vascular diseases presents several burgeoning opportunities, such as ongoing advancements in gene and stem cell therapies and the adoption of telemedicine, mobile health applications, and wearables for patient management.

KEY MARKET STATISTICS
Base Year [2023] USD 29.83 billion
Estimated Year [2024] USD 32.21 billion
Forecast Year [2030] USD 53.51 billion
CAGR (%) 8.70%

Regional Insights

The United States represents a significant market for collagen vascular diseases (CVDs), driven by a well-established healthcare infrastructure, patient awareness, and a high incidence of autoimmune diseases. The presence of leading pharmaceutical companies focusing on innovation, coupled with supportive government policies, contributes to market expansion. In South America, the collagen vascular diseases market is expanding as healthcare access improves and the population becomes more aware of these diseases. Government initiatives to strengthen healthcare provision and international collaborations for medical research are expected to propel the market further. The EU's need for collagen vascular diseases is characterized by the availability of universal healthcare systems and a strong focus on research and development. Stringent regulations regarding drug approvals ensure a high standard of care. Consumers in this region expect state-of-the-art treatment facilities and are driven by the effectiveness and safety profiles of treatments. The Middle East is experiencing a rise in autoimmune disorders, including collagen vascular diseases, and due to a developing healthcare sector, there is a reliance on international guidelines and medications. Africa's capacity to manage collagen vascular diseases is varied, with a greater prevalence of these conditions and a scarcity of advanced treatments in many regions. China's market is rapidly expanding with a shift towards modern healthcare systems, and increased investment in healthcare by the government and private sector, paired with greater access to global pharmaceuticals, is influencing customer needs. Japan's market reflects a high degree of technological integration in healthcare, with a consumer base inclined towards innovation and treatment quality.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Collagen Vascular Diseases Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Growing awareness and understanding of collagen vascular diseases
      • Rising incidence of autoimmune diseases globally
      • Improved healthcare infrastructure and increased accessibility to medical services
    • Market Restraints
      • High cost associated with advanced treatments and medications
    • Market Opportunities
      • Ongoing advancements in gene and stem cell therapies
      • Adoption of telemedicine, mobile health applications, and wearables for patient management
    • Market Challenges
      • Stringent government regulations and approval processes
  • Market Segmentation Analysis
    • Product: Increasing usage of biopsy kits in collagen vascular diseases
    • Indication: Increasing utilization for indicating dermatomyositis
    • End-Use: Expanding usage among diagnostic centers & laboratories to diagnose various health conditions
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Collagen Vascular Diseases Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Collagen Vascular Diseases Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis

Quest Diagnostics and Scipher Medicine have forged a multi-year partnership to widen the scope of diagnostic capabilities for rheumatoid arthritis (RA) management, leveraging the pioneering PrismRA test. This molecular signature response classifier (MSRC) facilitates the prediction of responses to TNF inhibitor therapies, which is crucial for managing RA. Quest's service extension to include advanced RNA extraction and next-generation sequencing ensures a more efficient assessment of patient responses to TNF inhibitors. The partnership capitalizes on Quest's nationwide network for specimen collection and sophisticated logistics, thereby enhancing patient access to precision diagnostic solutions. [Published On: 2023-11-28]

FDA Approves First Tocilizumab Biosimilar For Treatment Of Rheumatoid Arthritis, JIA

Biogen has announced the FDA approval of Tofidence, the inaugural tocilizumab biosimilar authorized for use in the U.S., offering new treatment options for individuals with rheumatoid arthritis (RA) and certain juvenile arthritis conditions. This milestone promises increased healthcare savings and broader therapeutic access, according to the details provided by the manufacturer. Tofidence has been validated based on rigorous data analysis, including a phase 1 and phase 3 study, affirming its safety and efficacy as a biosimilar alternative to the reference drug Actemra. [Published On: 2023-10-02]

American College of Rheumatology Launches New Toolkit Aimed at Measuring Rheumatoid Arthritis Outcomes

The American College of Rheumatology (ACR) has introduced its innovative Rheumatoid Arthritis (RA) Measures Toolkit, a comprehensive resource designed to dramatically enhance the quality of RA patient care. Emphasizing the importance of regular monitoring and individualized therapy, the toolkit offers invaluable tools, including training guides, multilingual outcome measure copies, and workflow samples, to ensure precise and effective tracking of disease activity and patient functionality. [Published On: 2023-08-09]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Collagen Vascular Diseases Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Collagen Vascular Diseases Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Apollo Health and Lifestyle Limited, Augurex Life Sciences Corporation, Bayer AG, Beckman Coulter, Inc., Bio-Rad Laboratories Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb, Eli Lilly and Company, Exagen Inc., F. Hoffmann-La Roche Ltd, Getinge AB, Gilead Sciences, Inc., Illumina, Inc., Laboratory Corporation of America Holdings, LeMaitre Vascular, Inc., Merck KGaA, Novartis AG, PerkinElmer, Inc., Pfizer Inc,, QIAGEN GmbH, Siemens AG, Thermo Fisher Scientific, Inc., and Trinity Biotech PLC.

Market Segmentation & Coverage

This research report categorizes the Collagen Vascular Diseases Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Diagnosis
      • Biopsy
      • Blood Test
      • Echocardiogram
      • Imaging Tests
      • Urinalysis
    • Treatments
      • Medications
      • Physical Therapy
  • Indication
    • Ankylosing Spondylitis
    • Dermatomyositis
    • Polyarteritis Nodosa
    • Polymyositis
    • Psoriatic Arthritis
    • Relapsing Polychondritis
    • Rheumatoid Arthritis
    • Scleroderma
    • Systemic Lupus Erythematosus
    • Vasculitis
  • End-Use
    • Diagnostic Centers & Laboratories
    • Hospitals & Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness and understanding of collagen vascular diseases
      • 5.1.1.2. Rising incidence of autoimmune diseases globally
      • 5.1.1.3. Improved healthcare infrastructure and increased accessibility to medical services
    • 5.1.2. Restraints
      • 5.1.2.1. High cost associated with advanced treatments and medications
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing advancements in gene and stem cell therapies
      • 5.1.3.2. Adoption of telemedicine, mobile health applications, and wearables for patient management
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent government regulations and approval processes
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Increasing usage of biopsy kits in collagen vascular diseases
    • 5.2.2. Indication: Increasing utilization for indicating dermatomyositis
    • 5.2.3. End-Use: Expanding usage among diagnostic centers & laboratories to diagnose various health conditions
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Collagen Vascular Diseases Market, by Product

  • 6.1. Introduction
  • 6.2. Diagnosis
  • 6.3. Treatments

7. Collagen Vascular Diseases Market, by Indication

  • 7.1. Introduction
  • 7.2. Ankylosing Spondylitis
  • 7.3. Dermatomyositis
  • 7.4. Polyarteritis Nodosa
  • 7.5. Polymyositis
  • 7.6. Psoriatic Arthritis
  • 7.7. Relapsing Polychondritis
  • 7.8. Rheumatoid Arthritis
  • 7.9. Scleroderma
  • 7.10. Systemic Lupus Erythematosus
  • 7.11. Vasculitis

8. Collagen Vascular Diseases Market, by End-Use

  • 8.1. Introduction
  • 8.2. Diagnostic Centers & Laboratories
  • 8.3. Hospitals & Clinics

9. Americas Collagen Vascular Diseases Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Collagen Vascular Diseases Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Collagen Vascular Diseases Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. Quest Diagnostics and Scipher Medicine Collaborate to Scale Precision Medicine Access for Patients with Rheumatoid Arthritis
    • 12.3.2. FDA Approves First Tocilizumab Biosimilar For Treatment Of Rheumatoid Arthritis, JIA
    • 12.3.3. American College of Rheumatology Launches New Toolkit Aimed at Measuring Rheumatoid Arthritis Outcomes
  • 12.4. Strategy Analysis & Recommendation

13. Competitive Portfolio

  • 13.1. Key Company Profiles
  • 13.2. Key Product Portfolio